Authored by Open Medicine, published on 2026-02-21 06:32:34.0
Dr. Kevin Kalinsky, Director of the Breast Cancer Program at the Winship Cancer Institute, Emory University and the Oncology Brothers review their current treatment approach to "Metastatic Hormone Receptor Positive (HR+) Breast Cancer Treatment Algorithm: Dr. Kevin Kalinsky."
Advanced / Metastatic Breast Cancer confirmed
ET (recurrence ≤12 mos of adj ET)
PIK3CA Mut+
Inavolisib + Palbo +
Fulvestrant
<p>INAVO120</p>
ESR1 mutation
<p>EMERALD Phase III</p>
Elacestrant /
Imlunestrant
T-DXd
(HER2 IHC ultra-low/low)
<p>DESTINY-Breast06</p>
Sacituzumab govitecan
(at least 2 prior lines of systemic rx)
<p>TROPiCS-02</p>
Dato-DXd
(post chemo)
<p>TROPION-Breast01</p>
Chemo
PIK3CA mutation
<p>SOLAR-1</p>
Alpelisib +
Fulvestrant
Chemo
Dato-DXd
(post chemo)
<p>TROPION-Breast01</p>
Sacituzumab govitecan
(at least 2 prior lines of systemic rx)
<p>TROPiCS-02</p>
T-DXd
(HER2 IHC ultra-low/low)
<p>DESTINY-Breast06</p>
PIK3CA / AKT1 / PTEN alteration
<p>CAPItello-291</p>
Capivasertib +
Fulvestrant
T-DXd
(HER2 IHC ultra-low/low)
<p>DESTINY-Breast06</p>
Sacituzumab govitecan
(at least 2 prior lines of systemic rx)
<p>TROPiCS-02</p>
Dato-DXd
(post chemo)
<p>TROPION-Breast01</p>
Chemo
gBRCA mutation
PARPi
Chemo
Dato-DXd
(post chemo)
<p>TROPION-Breast01</p>
Sacituzumab govitecan
(at least 2 prior lines of systemic rx)